Pathogenesis and treatments for high altitude pulmonary hypertension: An updated review
- 3 June 2025
- journal article
- review article
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 370 (3) , 285-290
Abstract
No abstract availableKeywords
Funding Information
- Key Research and Development Program of Sichuan Province (GYYX24018)
- 1.3.5 Project of Center for High Altitude Medicine, West China Hospital of Sichuan University
- Sichuan University
- the Key Research and Development Program of Sichuan Province (2024YFFK0084)
This publication has 49 references indexed in Scilit:
- NLRC3 deficiency promotes hypoxia-induced pulmonary hypertension development via IKK/NF-κB p65/HIF-1α pathwayExperimental Cell Research, 2023
- Single-cell analysis of peripheral blood from high-altitude pulmonary hypertension patients identifies a distinct monocyte phenotypeNature Communications, 2023
- Protection function of 18β-glycyrrhetinic acid on rats with high-altitude pulmonary hypertension based on 1H NMR metabonomics technologyAnalytical Biochemistry, 2021
- Macitentan Attenuates Chronic Mountain Sickness in Rats by Regulating Arginine and Purine MetabolismJournal of Proteome Research, 2020
- AMPKα2 deficiency exacerbates hypoxia-induced pulmonary hypertension by promoting pulmonary arterial smooth muscle cell proliferationJournal of Physiology and Biochemistry, 2020
- Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlandersEuropean Journal of Human Genetics, 2018
- Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertensionNature Communications, 2015
- Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitudeRespiratory Physiology & Neurobiology, 2009
- Free radicals, oxidative stress, and antioxidants in human health and diseaseJournal of the American Oil Chemists' Society, 1998
- HIGH-ALTITUDE PULMONARY HYPERTENSIONThe Lancet, 1965